SCHEMBL3298201

SCHEMBL3298201

CC(C)(C)C(C(=O)O)N(c1ccc2c(ccn2-c2cc(C(=O)N3CCOCC3)ccn2)c1)S(=O)(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.34
LMNA P02545 2/20 0.34
HPGD P15428 4/20 0.33
KMT2A Q03164 2/20 0.33
B3GNT2 Q9NY97 1/20 0.33
PKM P14618 2/20 0.33
PIK3CA P42336 1/20 0.33
SYK P43405 1/20 0.32
CCNT1 O60563 1/20 0.32
CDK9 P50750 1/20 0.32
TSHR P16473 1/20 0.32
MAPK1 P28482 1/20 0.32
HSD11B1 P28845 1/20 0.32
RAB9A P51151 1/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
PLA2G4A P47712 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3300694 0.89 ACLY (0.36) SMN1; SMN2PIK3CAMAPK1
SCHEMBL3303822 0.89 HTR2C (0.31) SMN1; SMN2LMNAHPGDKMT2AMAPK1
SCHEMBL3298897 0.88 IRAK4 (0.31)
SCHEMBL3298169 0.88 GRM5 (0.32) SMN1; SMN2LMNAHPGDMAPK1RAB9A
SCHEMBL3301412 0.86 KDM4E (0.36) LMNAKMT2APKMRAB9AKDM4E
SCHEMBL3294888 0.86 IRAK4 (0.33)
SCHEMBL3303924 0.86 IRAK4 (0.32)
SCHEMBL3295496 0.85 CCR9 (0.35) SMN1; SMN2LMNAKMT2APIK3CARAB9A
SCHEMBL3301125 0.85 ROCK1 (0.34)
SCHEMBL3298548 0.85 DGAT1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093703-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093703-A1 SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS PYGL, PYGM, G6PC1 SMN1; SMN2 2493/4885LMNA 1244/4885HPGD 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.